JYSS BIO Completes Two Rounds of Financing with Total Amount of ￥200M

(VCBeat) July. 26, 2021 -- Recently, Zhejiang JYSS Bio-Engineering Co., Ltd. ("JYSS BIO"), a biopharmaceutical Single-Use system provider, has completed two rounds of financing within six months, with the amount of each round of financing reaching hundreds of millions.

The Series A round was led by Matrix Partners China, with participation from Sinowisdom and Jiayuan Capital. The Series B was led by China Merchant Bank International Capital. Sherpa Healthcare Partners, CITIC Medical Fund, C&D Emerging Investment and the existing investors in Series A also participated in the Series B round, with Golu Capital acting as the exclusive financial advisor. The funds raised will be mainly used for the development and capacity expansion of new disposable bioreactors, disposable liquid storage and distribution systems, disposable cell culture bags, breathing bags, sampling bags, liquid storage bags and other types of consumables, in order to meet the continuous soaring customer demand.

JYSS BIO was founded in 2014 as the first high-tech enterprise in China to realize the Single-Use bioreactor and Single-Use assemblies localization in Mainland China. At present, the company has 3,200 square meters of GMP consumables production workshop, 4,500 square meters of partial B+A grade liquid bag and general consumables process bag production workshop is being designed; 3,500 square meters of bioreactor production workshop. The company's business activities strictly follow ISO9001, ISO14001 management system operations. Perfect R&D, production, sales system for the sustainable development of the company has provided a strong driving force.

JYSS BIO provides customers with the whole process and technology solutions of biopharmaceutical from R&D to industrialization, and can widely serve the institutions and enterprises of recombinant protein drugs, gene therapy products, human vaccines, veterinary vaccines, and others. Single-Use bioreactor is the knockout product of the company, and its oxygen transfer mechanism has got worldwide's invention patents. 

Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant industry-leading companies. Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have gone on to profitable M&A events. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.

Sherpa was founded in 2018 and has now become an influential healthcare VC firm in the industry. Sherpa has invested in leading companies in many key areas, such as Pharma, GeneTech, MedTech and Medical services. From 2011 to 2020, the team has gone through 4 vintage-year cycles of multiple U.S dollar funds and RMB funds and made over 100 investments, with a total of 1 billion U.S dollars (including the RMB equivalent).